Abstract: The present invention provides a process for the preparation of an MR contrast agent, said process comprising:

Abstract: The invention relates to a method of magnetic imaging (MR) of a living sample comprising the steps of hyperpolarizing a hyperpolarizable gas ex-vivo and transferring the nuclear polarization from the hyperpolarized gas to the nuclei of an MR imaging agent, that is not hyperpolarizable, that is exposed to a uniform magnetic field and that is introduced in contact to the hyperpolarizable gas, separating the hyperpolarizable gas from the MR imaging agent, administering the MR imaging agent to the living sample, exciting NMR transitions in the nuclei of the imaging agent and detecting an NMR signal thereof.

Abstract: The present invention provides a method of magnetic resonance investigation of a sample, preferably of a human or non-human animal body, said method comprising:

Abstract: This invention provides a method of MR investigation of a sample, the method comprising: (i) placing in a uniform magnetic field a composition comprising an OMRI contrast agent and an MR imaging agent containing nuclei (MR imaging nuclei) capable of emitting magnetic resonance signals (e.g. the primary magnetic field B0) and capable of exhibiting a T1 relaxation time of 6 s or more (at 37° C. in D2O in a field of 7T); (ii) exposing the composition to a first radiation of a frequency selected to excite electron spin transitions in the OMRI contrast agent; (iii) optionally but preferably separating the whole, substantially the whole, or a portion of said OMRI contrast agent from said MR imaging agent; (iv) administering said MR imaging agent to said sample, (v) exposing the sample to a second radiation of a frequency selected to excite nuclear spin transitions; (vi) detecting magnetic resonance signals from the sample; and (vii) optionally, generating an image or dynamic flow data from the detected signals.

Abstract: The present invention provides a method of magnetic resonance investigation of a sample, preferably of a human or non-human animal body, said method comprising the step of ex vivo polarisation of a high T1 agent and wherein the polarising agent is optionally seperated from the high T1 agent before the high T1 agent is administered to the sample.

Abstract: The present invention relates to compounds of formula (I), any of it enantiomers, or any mixture thereof, or a pharmaceutically acceptable acid addition salt thereof, wherein R1, R2, R3, R4, R11, R12, R13, R14 and R15 each independently are hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, nitro, cyano, amino, acyl, alkylamino, dialkylamino, aminocarbonyl, or acylamino; R5 is hydrogen, alkyl, alkoxyalkyl, or phenylalkyl; X is —CH2—Z—, Z—CH2—, NH—CO—, —CO—NH—, or —CH═CH—; wherein Z is O, S, CH2, or NH; Y is O, —CH2—W—, —W—CH2—; wherein W is O, or S; and n is 0, 1 or 2. The compounds are useful in the treatment of psychotic disorders.

Abstract: The present invention discloses compounds of the formula wherein the dotted bonds are optional extra bonds allowing any tautomeric isomers compatible with substituents X and R3; R3 is non-existing, hydrogen, or alkyl; X is O, S, imino, alkoxy, alkylthio, or amino; R1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, acyl, acylalkyl, alkoxyalkyl, dialkoxyalkyl, or phenylalkyl which may be substituted with alkyl, halogen, amino, nitro or cyano; and R4, R5, R6 and R7 independently of each other are hydrogen; halogen; amino; nitro; CN; CF3; COOH; COO-alkyl; alkyl; acyl; alkoxy; —(CH2)n,—OH wherein n is 0, 1, 2, or 3; —(CH2)m—O-alkyl wherein m is 0, 1,2, or 3; —(CH2)p—O-acyl wherein p is 0, 1,2, or 3; or a pharmaceutically acceptable addition salt thereof.

Abstract: The present invention discloses compounds of the formula ##STR1## any of its enantiomers or any mixture thereof, or a pharmaceutically-acceptable addition salt thereof, wherein X, Ar, R, R.sup.1, R.sup.2, n are as defined herein.

Abstract: Compounds of structure (I) in which R is C.sub.1-8 alkyl(phenyl)p, C.sub.2-8 alkenyl(phenyl)p, C.sub.2-8 alkenyl(phenyl)p, C.sub.3-8 cycloalkyl or C.sub.1-8 alkylC.sub.3-8 cycloalkyl; p is 0 to 2; n is 0 to 6; A is a bond, oxygen, sulphur or NR.sup.1 ; R.sup.1 is hydrogen, C.sub.1-8 alkylphenylC.sub.1-4 alkyl; m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, and salts thereof processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy, in particular as calcium blocking agents.

Abstract: The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.3, R.sup.4, R.sup.6 and R.sup.7 each have the meanings set forth in the specification.The compounds are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

Abstract: The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.3, R.sup.4, R.sup.6 and R.sup.7 each have the meanings set forth in the specification.The compounds are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

Abstract: The present invention discloses compounds of the formula ##STR1## or a pharmaceutically-acceptable addition salt thereof whereinR' and R" independently of each other are hydrogen or alkyl, or R' and R" together form a 3 to 6 membered alkylene chain;one of R.sup.1 and R.sup.2 is aryl which may be substituted one or more times with halogen, CF.sub.3, CN, OH, alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxy, amino, nitro, sulphamoyl, tetrazolyl, CO.sub.2 H, CO.sub.2 -alkyl and the other of R.sup.1 and R.sup.2 is hydrogen, halogen, alkoxy, amino or alkyl; andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently of each other are hydrogen, halogen, amino, nitro, CN, OH, CF.sub.3, alkyl or alkoxy; and n is 0 or 1; provided that neither of R.sup.1 and R.sup.2 is phenyl or substituted phenyl when n is 0.The compounds are useful as pharmaceuticals, for example, in the treatment of ischemia, anoxia, migraine and psychosis.

Abstract: The present invention discloses compounds of the formula ##STR1## wherein X is C;Y is C;R.sup.4 to R.sup.7 and R.sup.11 to R.sup.13 are as defined herein; or a pharmaceutically-acceptable addition salt thereof. The compounds are useful as pharmaceuticals, for example, in the treatment of stroke, ischemia, anoxia, migraine and psychosis.

Abstract: The present invention discloses compounds of the formula ##STR1## wherein R' and R" independently of each other are hydrogen or alkyl, or R' and R" together form a 3 to 6 membered alkylene chain;n is 1 or 2;R.sup.1 is phenyl which may be substituted one or more times with halogen, CF.sub.3, alkoxy, alkyl, or amino; andR.sup.4, R.sup.5, R.sup.6 and R.sup.7 independently of each other are hydrogen, halogen, amino, CF.sub.3, alkyl or alkoxy; or a pharmaceutically-acceptable addition salt thereof.The compounds are useful as pharmaceuticals, for example, in the treatment of ischemia, anoxia, migraine and psychosis.

Abstract: The application discloses benzimidazole derivatives, pharmaceutical preparations comprised the compounds, their preparation and use in the treatment of disorders of the Central Nervous System such as ischemia, migraine, epilepsia, psychosis, Parkinsonism and depression.